SCHEMBL25267754

SCHEMBL25267754

COC[C@H](C(=O)Cl)N1C(=O)CCC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC1A2 P43004 1/20 0.32
LMNA P02545 1/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA3 P07451 1/20 0.30
CA4 P22748 1/20 0.30
CA6 P23280 1/20 0.30
CA5A P35218 1/20 0.30
CA7 P43166 1/20 0.30
CA9 Q16790 1/20 0.30
CA13 Q8N1Q1 1/20 0.30
CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25267755 1.00 ALDH1A1 (0.39) ALDH1A1PKMKMT2AATMHPGD
SCHEMBL25268821 0.84 ALDH1A1 (0.51) ALDH1A1PKMKMT2AATMHPGD
SCHEMBL25216154 0.84 ALDH1A1 (0.51) ALDH1A1PKMKMT2AATMHPGD
SCHEMBL31078067 0.73 ALDH1A1 (0.45) ALDH1A1PKMKMT2AATMHPGD
SCHEMBL25220232 0.73 ALDH1A1 (0.49) ALDH1A1KMT2AHPGDLMNA
SCHEMBL25270229 0.73 ALDH1A1 (0.49) ALDH1A1KMT2AHPGDLMNA
SCHEMBL8538536 0.73 ALDH1A1 (0.40) ALDH1A1PKMLMNACA12CA1
SCHEMBL31307515 0.71 ALDH1A1 (0.46) ALDH1A1PKMKMT2AATMHPGD
SCHEMBL8537730 0.70 ALDH1A1 (0.38) ALDH1A1PKM
SCHEMBL15511368 0.69 CA1 (0.41) ALDH1A1PKMKMT2AATMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
EP-4444728-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 EP disclosed
WO-2023107487-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 ALDH1A1 1527/4885PKM 1470/4885KMT2A 3897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.